What Relvare Treats: Main Uses and Benefits

The core therapeutic function of Relvare is the maintenance treatment of chronic breathing conditions. Relvare is commonly used as a core component of daily, long-term supportive management for two primary chronic obstructive airway diseases: Chronic Obstructive Pulmonary Disease (COPD) in adults, and persistent asthma in adults and adolescents.

Supportive Management of Obstructive Symptoms

This medication is commonly used to address clusters of recurrent breathing difficulties, including persistent shortness of breath, wheezing, and chest tightness, which are symptoms that interfere with daily functioning. The therapeutic benefit is supportive relief, and it may assist with maintaining functional stability to support general well-being during symptomatic phases throughout the day and night. This continuous support may help patients cope more steadily with the difficult, chronic manifestations of their disease.

Stabilization and Support During Symptom Flare-Ups

A key therapeutic benefit is the medication's role in stabilizing the underlying disease process. It is relevant in conditions marked by heightened risk of acute symptomatic episodes and plays a role in contributing to easing the overall symptom load during episodes of heightened symptoms, which is particularly helpful for managing exacerbations.

Quick Fact
Relief for	Persistent Shortness of Breath and Wheezing
Used in	COPD and Persistent Asthma Maintenance
Main Goal	Assists with Maintaining Functional Stability

Regulatory References

1. European Medicines Agency overview

Official Population Eligibility for Relvare

Relvare (Fluticasone Furoate/Vilanterol) is governed by strict regulatory eligibility rules defining who may use the medicine. The medication is intended solely for long-term maintenance and must not be initiated for acute, rapidly deteriorating episodes of asthma or COPD.

Approved Populations: Use is established for adults (18 years and older) requiring maintenance treatment for COPD or asthma. For asthma, use is also approved for adolescents aged 12 years and older.

Absolute Contraindications: Relvare is strictly contraindicated in patients with a history of hypersensitivity to fluticasone furoate, vilanterol, or any of the excipients, including severe allergy to milk proteins.

Conditional and Restricted Use:

• Age: Use in children under 12 years old for asthma is not established and is not recommended.
• Hepatic Function: Patients with moderate or severe liver impairment must adhere to the lower labeled dosage strength.
• Other Conditions: Caution is required when using this medicine in patients with severe cardiovascular disorders or specific metabolic and infectious conditions, such as uncontrolled diabetes mellitus or active tuberculosis.
• Pregnancy/Lactation: Use during pregnancy or breastfeeding is conditional and must only proceed after a careful assessment of risks versus benefits.

Interactions with other medicines and products

The official regulatory documentation defines specific interaction patterns for Relvare, encompassing formal prohibitions, metabolic clearance risks, and pharmacodynamic effects.

Formal Regulatory Restrictions

The most stringent restriction is the formal prohibition on co-administration with other medicinal products containing a Long-Acting Beta₂-Agonist (LABA). This constraint is required by regulatory bodies to prevent the established risk of overdose resulting from excessive adrenergic activity. No specific timing separation rules for administration with any substance are documented in the official labeling.

Metabolic and Exposure Interactions

A core pharmacokinetic interaction is documented with Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors, such as ketoconazole. Since both active components are substrates for the CYP3A4 enzyme, co-administration results in inhibited metabolism, which in turn leads to a significant increase in the systemic exposure (AUC and C max) of both Fluticasone and Vilanterol.

Pharmacodynamic Effects

Several interactions are based on combined pharmacological effects. Beta-blockers (both selective and non-selective) may antagonize the bronchodilatory action of Vilanterol. Extreme caution is documented for co-use with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs), as these agents may potentiate the vascular effects of Vilanterol. Furthermore, the use of non-potassium-sparing diuretics may worsen the risk of hypokalemia and ECG changes associated with beta2-agonist use.

Population-Specific Constraint

For patients with moderate or severe hepatic impairment, the official label notes a reduction in the clearance of the active components, which results in increased systemic exposure compared to healthy individuals.

How Relvare Works

This section describes the core biological actions of Relvare, detailing the systems and pathways it influences at the molecular level.

Primary Mechanism: Selective Receptor System Modulation

Relvare's action begins by targeting and modulating specific receptor or enzyme systems, influencing signaling mechanisms associated with heightened or altered activity. This initial, targeted binding allows Relvare to initiate or suppress specific signaling events, resulting in the modulation of processes driven by distinct signaling patterns.

Influencing Signal Transduction Cascades

Following target engagement, Relvare acts within well-characterized molecular cascades, modifying early molecular steps that influence subsequent signal propagation. This mechanism is relevant in systems where targeted pathway adjustment occurs, influencing pathway activity dynamics associated with heightened signaling.

Modifying Pathway Activity

Relvare's activity results in the modulation of specific pathway activity. Its influence on central and/or peripheral pathways reduces the magnitude of mediator activity, resulting in pathway-level modifications.

How to Use Relvare

Relvare (fluticasone furoate/vilanterol) is a fixed-dose combination medicine administered exclusively via oral inhalation as a dry powder, using a specialized proprietary inhaler device.

This medication is designed for long-term maintenance treatment of chronic respiratory conditions and is specifically patterned for once-daily use. It must be taken at the same time every day and is not intended for the immediate relief of acute breathing problems, which requires a separate short-acting inhaler.

---

Official Dosing and Administration Protocol

The established usage protocols define specific strengths for certain conditions. For COPD, the official dosing is limited to one inhalation of the 92 mcg/22 mcg strength once daily. For Asthma (in adults and adolescents aged 12 and older), patients may be prescribed either the 92 mcg/22 mcg or the 184 mcg/22 mcg strength, once daily.

Instruction Domain	Official Guideline
Frequency	Once daily (q.d.); do not exceed one inhalation per 24 hours.
Hepatic Adjustment	The maximum strength is limited to 92 mcg/22 mcg for patients with moderate to severe liver impairment.
Post-Use Procedure	Rinse mouth with water and spit out immediately after inhalation.
Missed Dose	If a dose is missed, the next dose should be taken at the usual time the following day. Double dosing is not permitted.

Safety and effectiveness for asthma maintenance have not been established in pediatric patients under 12 years of age.

Research Evidence / Overview of Studies for Relvare

---

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research into this combination medicine for COPD maintenance has primarily centered on large-scale, international Randomized Controlled Trials (RCTs). These studies were used to explore patterns when comparing the medicine to a placebo (inactive treatment), using one of the components alone, or using other available treatments. The research focused on adults who have moderate-to-severe COPD and a history of having had previous flare-ups.

Studies monitored several key factors. A major focus was evaluating the annual rate of moderate or severe COPD exacerbations, which are outcomes describing episodic or acute changes requiring additional medical treatment. Research also examined changes measured during the study period related to lung function, such as the Forced Expiratory Volume in 1 second (FEV1), a measure of airflow.

Findings describe findings related to the measured rate of episodic or acute changes compared to specific control groups. Research described changes measured in lung function tests when the combination was compared to the use of the corticosteroid component alone or placebo. These findings help contextualize how patients reported their experience over the study period.

---

Evidence for Use in Persistent Asthma

For persistent asthma, studies explored this combination medicine for long-term use in adults and adolescents (age 12 and older) whose symptoms were not adequately managed by an inhaled corticosteroid alone. The primary study types were Randomized Controlled Trials of various durations, including non-inferiority studies that compared this medicine to certain existing combination treatments.

Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning. Key outcomes that studies monitored included measures of asthma control via standardized testing, changes in lung function (Trough FEV1), and the frequency of severe asthma exacerbations (flare-ups).

Studies reported how symptoms evolved in the observed populations, particularly when comparing the combination to the single inhaled corticosteroid component. The evidence contributes to understanding symptom patterns, with some studies indicating outcomes related to the time until a patient's first severe exacerbation in the combination group compared to other groups.

---

Research Gaps and Areas of Uncertainty

Certainty remains low in specific areas of the research landscape. A key limitation noted by regulators is related to the two available dosage strengths. The higher dosage of the inhaled corticosteroid component was studied for both indications, but research did not find a greater measured change in terms of lung function or exacerbation reduction compared to the lower dosage.

Furthermore, when comparing the doses studied, research described observed variations in outcomes for the higher dose, including for certain physical or systemic outcomes. Data for the pediatric population younger than 12 years of age remain insufficient.

Key Studies & References

1. Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease (Expert Commentary)

Common questions about Relvare (FAQ)

---

Q: How long does it usually take for Relvare to start working?

According to official clinical trial data, signs of improved lung function, which is measured by a standard test called Forced Expiratory Volume in 1 second (FEV1), can often be observed as quickly as 15 minutes after the first dose. This initial change suggests the onset of the bronchodilator's effect, though the full maintenance benefit develops with consistent daily use.

Q: Does Relvare cause weight gain or loss?

Official regulatory information suggests that weight change is not a common side effect reported in trials. However, the inhaled corticosteroid component can, in rare cases, lead to systemic effects like hypercorticism. One of the symptoms described for this condition is weight gain, particularly around the midsection.

Q: Can Relvare be used by people who have [common condition]?

Official labeling advises that caution is needed when prescribing this medicine to individuals with certain health histories. This includes patients with cardiovascular disorders, a history of seizures, unmanaged infections, or diabetes. The prescribing information details specific warnings related to these conditions.

Q: Are there any foods or drinks I should avoid while using Relvare?

Official documents caution about a risk of interaction with strong inhibitors of the CYP3A4 enzyme, which processes the medicine in the body. Grapefruit juice can sometimes act as a strong inhibitor. For this reason, patients should be aware of the potential for increased exposure to the drug when consuming such products.

Q: Can Relvare cause mood changes or depression?

Clinical trial data indicates that adverse reactions affecting the nervous system have been reported. These have included feelings of anxiety, as well as other psychiatric disorders. This information is noted in the official safety documents.

Q: Is it true that Relvare has a Black Box Warning?

Official FDA labeling does include a Boxed Warning, which is related to the Long-Acting Beta2-Adrenergic Agonist (LABA) class of medicines. This is a general class-effect warning regarding an increased risk of asthma-related death. However, clinical data for this specific combination product did not identify a statistically significant increased risk of asthma-related death.

Q: Can people with liver or kidney issues use Relvare?

Official information states that patients with renal (kidney) impairment do not typically require a dosage adjustment. However, patients with moderate to severe hepatic (liver) impairment must be monitored closely. For these individuals, regulatory guidelines specify that they should not exceed the lower approved dosage strength.

Q: How long does Relvare stay in your system?

The drug's presence in the body can be estimated through pharmacokinetics, which is the study of how a drug is processed. The plasma elimination half-life for vilanterol, one of the active ingredients, is approximately 11 hours. The half-life describes the time it takes for the concentration of a substance in the body to be reduced by half.

Q: Can I use Relvare if I am already taking supplements?

The official Patient Counseling Information advises that individuals inform their healthcare provider about all products they are taking. This includes prescription medicines, over-the-counter drugs, vitamins, and any herbal or other dietary supplements. Sharing this information helps inform the provider's overall safety assessment regarding potential interactions or additive effects.

Q: Is Relvare safe to take long-term?

The medicine is prescribed for long-term maintenance treatment. However, long-term use is associated with a risk of systemic corticosteroid effects. These effects include the potential for decreased bone mineral density and ocular issues like glaucoma or cataracts.

Q: Does Relvare affect sleep patterns?

Clinical trial data included reports of insomnia, or trouble sleeping, as an adverse reaction. Patients experiencing changes in sleep patterns should note that this has been reported in official safety documents.

Q: What are the possible signs of an allergic reaction to Relvare?

Hypersensitivity reactions have been reported in official safety documents. Signs of these reactions include rash, hives (urticaria), and angioedema. Angioedema is characterized by swelling of the face, tongue, or throat.

Q: Can I drink alcohol while taking Relvare?

Official regulatory text does not list a direct interaction between this medicine and alcohol. However, the beta2-agonist component can influence the cardiovascular system and blood sugar levels. Patients should be aware of how alcohol consumption might overlap with or potentially worsen these systemic effects.

Q: Are there any known interactions between Relvare and herbal products?

The medicine carries a risk of interaction with strong inhibitors of the CYP3A4 enzyme, a category that includes some herbal products. This interaction can increase the body's exposure to the drug's components. For this reason, official patient information advises individuals to notify their healthcare provider of all herbal products and supplements they use.

Q: Is it normal to feel [mild, non-serious symptom] when first starting Relvare?

Official reports from clinical trials indicate that headache, cough, and nasopharyngitis (inflammation of the nose and throat, similar to cold symptoms) are common adverse reactions. These effects are based on large patient populations and are among the symptoms noted for discussion with a healthcare professional.

Q: What happens if I accidentally take too much Relvare?

The official overdose section states that taking too much can result in exaggerated effects of the beta2-agonist component. These effects may include cardiovascular symptoms like chest pain, a significantly increased heart rate, and elevated blood pressure. Hypokalemia, which is low potassium in the blood, is also a potential risk.

Q: Does Relvare cause changes in blood pressure?

The beta2-agonist component of the medicine is known to potentially cause clinically significant cardiovascular effects in certain patients. These effects are reported in official warnings and may include changes such as an increase in heart rate and blood pressure.

Q: Do I need a special monitoring while using Relvare?

Regulatory warnings indicate that patients using this medicine long-term may require specific monitoring for systemic effects. This includes monitoring for potential bone mineral density loss and periodic eye examinations to check for conditions like glaucoma or cataracts. Blood glucose and potassium levels may also be checked due to potential medication effects.

Q: Can I use Relvare if I have a history of seizures?

Official regulatory documents advise that the medicine should be used with caution in patients who have a history of convulsive disorders, such as seizures. This is a safety consideration noted in the product's warning section.

Q: Is Relvare approved for all stages of [disease or condition]?

The medicine is officially indicated for the long-term maintenance treatment of airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD). It is also approved for the maintenance treatment of persistent asthma in adults and adolescents aged 12 and older. The official labeling describes the populations studied for these specific maintenance purposes.

Q: What should I tell my doctor before starting Relvare?

Official patient counseling information emphasizes the importance of sharing a complete health history with the prescribing doctor. Key areas to discuss include any heart, liver, or seizure problems, as well as current infections or high blood pressure. Official guidance emphasizes the need to disclose whether an individual is pregnant, breastfeeding, or taking any other medicines or supplements.

Q: Is it common to have stomach issues with Relvare?

Gastrointestinal disorders were reported as adverse reactions during clinical trials, based on official safety data. Abdominal pain is an example of a gastrointestinal issue that has been reported in patients using this medicine.

Q: What is the success rate of Relvare mentioned in clinical trials?

Official reports from clinical trials focus on measured outcomes rather than a single 'success rate'. Studies indicate that the medicine significantly improved the measured lung function, specifically trough FEV1, in both COPD and asthma patients. Furthermore, the trials showed a reduction in the annual rate of COPD exacerbations compared to the placebo group.

How to Store and Dispose of Relvare

The Relvare (Fluticasone Furoate/Vilanterol) Ellipta inhaler must be stored under specific environmental conditions to maintain stability, as defined by regulatory labeling.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at room temperature, generally below 30 C. Do not freeze.
Protection	Keep the inhaler in its original sealed foil tray until first use to protect it from moisture. Protect from direct heat and light.
Shelf-Life	The product must be discarded 6 weeks after the foil tray is opened, even if doses remain.
Safety	Keep the medicine out of the sight and reach of children.

Disposal

Expired or unused inhalers must be disposed of according to local pharmaceutical waste regulations. The preferred method is using a medication take-back program. If this is unavailable, the product should be secured, mixed with an undesirable substance (such as dirt), and sealed in a bag for disposal in the household trash.